ArticleJournal for immunotherapy of cancer2018
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
Ahmad Tarhini et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
44 papers cite it
this paperpooled ittrialcites it